Thermo Fisher Scientific Inc. $TMO Holdings Decreased by R.H. Dinel Investment Counsel Inc.

Key Points

• R.H. Dinel Investment Counsel Inc. reduced its holdings in Thermo Fisher Scientific Inc. by 2.9%, owning 19,746 shares valued at approximately $8,006,000 as of its latest SEC filing.
• Wall Street analysts have varying outlooks on Thermo Fisher, with a consensus rating of "Moderate Buy" and an average price target of $588.35 per share.
• The company reported $5.36 EPS for the last quarter, exceeding estimates, and its shares are set to pay a quarterly dividend of $0.43 on October 15th.

R.H. Dinel Investment Counsel Inc. reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,746 shares of the medical research company's stock after selling 585 shares during the period. Thermo Fisher Scientific accounts for about 5.3% of R.H. Dinel Investment Counsel Inc.'s investment portfolio, making the stock its 7th largest holding. R.H. Dinel Investment Counsel Inc.'s holdings in Thermo Fisher Scientific were worth $8,006,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in TMO. Bernard Wealth Management Corp. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $25,000. CBIZ Investment Advisory Services LLC boosted its holdings in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after acquiring an additional 33 shares in the last quarter. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $30,000. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter worth about $30,000. Finally, Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the 1st quarter worth about $31,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent analyst reports. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. William Blair started coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating on the stock. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $480.02 on Monday. The firm's 50 day simple moving average is $472.01 and its two-hundred day simple moving average is $448.95. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market capitalization of $181.26 billion, a P/E ratio of 27.76, a P/E/G ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the firm earned $5.37 EPS. The company's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.